Clinical trials: brca2 Mutation Carrier
Adult Solid Neoplasm, BRCA1 Mutation Carrier
ABT-888 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors
This phase I trial is studying the side effects and best dose of giving ABT-888 together with gemcitabine hydrochloride in treating patients with advanced solid tumors.
- Conditions
- Adult Solid Neoplasm, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier
- Trial name
- NCT01154426
- Testing
- Diagnostic Laboratory Biomarker Analysis, Gemcitabine Hydrochloride, Pharmacological Study
- Where
- 4 sites in United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
BRCA1 Mutation Carrier, BRCA2 Mutation Carrier
Soy Isoflavones Supplementation in Treating Women at High Risk For or With Breast Cancer
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. The use of soy isoflavones supplements may prevent or treat early stage breast cancer.
- Conditions
- BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ
- Trial name
- NCT01219075
- Testing
- soy isoflavones, questionnaire administration, magnetic resonance imaging
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- University of Southern California
brca1 Mutation Carrier, brca2 Mutation Carrier
Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation
RATIONALE: Letrozole may prevent breast cancer in postmenopausal women with a BRCA1 or BRCA2 mutation. PURPOSE: This randomized phase III trial is studying letrozole to see how well it works compared with a placebo in preventing…
- Conditions
- brca1 Mutation Carrier, brca2 Mutation Carrier, Breast Cancer, Hereditary Breast/Ovarian Cancer (brca1, brca2)
- Trial name
- LIBER (NCT00673335)
- Testing
- letrozole
- Where
- 23 sites in France
- Volunteers
- 170 people
- Sponsor
- UNICANCER
Metastatic Breast Cancer
Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer
The primary objective of the study is to assess the progression-free survival (PFS) of oral veliparib in combination with TMZ or in combination with carboplatin and paclitaxel compared to placebo plus carboplatin and paclitaxel…
- Trial name
- NCT01506609
- Testing
- Veliparib, Carboplatin, Temozolomide
- Where
- 120 sites in United States, Argentina and 18 more
- Volunteers
- 294 people
- Sponsor
- AbbVie
BRCA1 Mutation, BRCA2 Mutation
FaCT Trial (Facilitated Cascade Testing Trial)
The purpose of this study is to assess an intervention that incorporates engagement strategies with a medical team navigator, an educational video and accessible genetic testing services to maximize the genetic testing and…
- Trial name
- NCT04613440
- Testing
- Family Letter (Standard of Care), Educational Video, Mailed Saliva Kit for Genetic Testing
- Where
- 3 sites in United States
- Volunteers
- 524 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Prostate Cancer
Analysing Outcomes After Prostate Cancer Diagnosis and Treatment in Carriers of Rare Germline Mutations
GENPROS aims to analyse the outcomes of patients with rare gene mutations in the cancer predisposition genes, BRCA1, BRCA2, HOXB13, and Lynch Syndrome, after a diagnosis of and treatment for prostate cancer (PCa).
- Trial name
- GENPROS (NCT02705846)
- Testing
- Observation of treatment outcomes via Questionnaire
- Where
- United Kingdom
- Volunteers
- 4,260 people
- Sponsor
- Institute of Cancer Research, United Kingdom
brca1 Mutation Carrier, brca2 Mutation Carrier
Carboplatin or Docetaxel in Treating Women With Metastatic Genetic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- brca1 Mutation Carrier, brca2 Mutation Carrier, Breast Cancer, Hereditary Breast/Ovarian Cancer (brca1, brca2)
- Trial name
- NCT00321633
- Testing
- carboplatin, docetaxel
- Where
- 25 sites in Australia, Israel and 4 more
- Volunteers
- 148 people
- Sponsor
- University College London Hospitals
brca1 Mutation Carrier, brca2 Mutation Carrier
Studying Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation Carriers
RATIONALE: Studying samples of DNA in the laboratory from women who are BRCA1/BRCA2 mutation carriers may help doctors learn more about cancer and identify biomarkers related to cancer.
- Conditions
- brca1 Mutation Carrier, brca2 Mutation Carrier, Breast Cancer
- Trial name
- NCT00897455
- Testing
- DNA analysis, mutation analysis, polymorphism analysis
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- Gynecologic Oncology Group
BRCA1 Mutation, BRCA2 Mutation
BRCA Mutation Carriers' Platform a Multicenter Study
Subjects who carry mutations in breast cancer susceptibility genes 1 and 2 (BRCA1 and BRCA2 genes) are at higher risk of developing cancers.
- Trial name
- BRCA_ENDORSE (NCT07253051)
- Testing
- Registration of clinical datas in the platform
- Where
- 40 sites in Italy
- Volunteers
- 10,000 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Atypical Ductal Breast Hyperplasia, Atypical Lobular Breast Hyperplasia
Group-Based Lifestyle Intervention in Measuring Biomarker Levels in Participants at High Risk for Breast Cancer
This randomized clinical trial studies a group-based lifestyle intervention or usual care in measuring biomarker levels in participants at high risk for breast cancer.
- Conditions
- Atypical Ductal Breast Hyperplasia, Atypical Lobular Breast Hyperplasia, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier
- Trial name
- DEEM (NCT01874184)
- Testing
- counseling intervention, behavioral dietary intervention, exercise intervention
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Washington
brca1 Mutation Carrier, brca2 Mutation Carrier
Deslorelin Combined With Low-Dose Add-Back Estradiol and Testosterone in Preventing Breast Cancer in Premenopausal Women Who Are at High Risk for This Disease
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Deslorelin combined with low-dose add-back estradiol and testosterone (given to replace hormones suppressed…
- Conditions
- brca1 Mutation Carrier, brca2 Mutation Carrier, Breast Cancer
- Trial name
- NCT00080756
- Testing
- therapeutic estradiol, deslorelin, therapeutic testosterone
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- City of Hope Medical Center
Breast Cancer, Metastatic Breast Cancer
ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer
The purpose of this research study is to find out if the combination of ABT-888 and temozolomide is safe and effective in treating patients with metastatic breast cancer.
- Conditions
- Breast Cancer, Metastatic Breast Cancer, BRCA1 Gene Mutation, brca2 Gene Mutation
- Trial name
- NCT01009788
- Testing
- ABT-888, temozolomide
- Where
- 3 sites in United States
- Volunteers
- 63 people
- Sponsor
- Steven J Isakoff, MD, PhD
Ovarian Cancer, Fallopian Tube Cancer
PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer
Of the approximately 21,000 cases of ovarian cancer diagnosed annually in the U.S, ten percent are attributed to hereditary syndromes, most commonly the result of mutations in the breast cancer susceptibility genes 1 or 2 (BRCA1…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms
- Trial name
- NCT02571725
- Testing
- Olaparib, Tremelimumab
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- New Mexico Cancer Research Alliance
brca1 Mutation Carrier, brca2 Mutation Carrier
Celecoxib in Preventing Cancer in Patients at High Risk for Ovarian Epithelial Cancer Who Are Undergoing Prophylactic Oophorectomy
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of celecoxib before prophylactic oophorectomy may be an effective way to prevent the development of…
- Conditions
- brca1 Mutation Carrier, brca2 Mutation Carrier, Ovarian Cancer
- Trial name
- NCT00084370
- Testing
- celecoxib, oophorectomy
- Where
- United States
- Sponsor
- University of Alabama at Birmingham
Basal-Like Breast Carcinoma, BRCA1 Mutation Carrier
Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy
This phase I trial studies the side effects and best dose of veliparib in treating patients with malignant solid tumors that do not respond to previous therapy.
- Conditions
- Basal-Like Breast Carcinoma, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Breast Carcinoma
- Trial name
- NCT00892736
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Veliparib
- Where
- 7 sites in United States
- Volunteers
- 98 people
- Sponsor
- National Cancer Institute (NCI)
brca1 Mutation Carrier, brca2 Mutation Carrier
Fenretinide in Preventing Ovarian Cancer in Participants Who Are at High Risk for Developing Ovarian Cancer and Planning to Undergo Surgery to Remove the Ovaries
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of fenretinide may prevent ovarian cancer.
- Conditions
- brca1 Mutation Carrier, brca2 Mutation Carrier, Ovarian Cancer
- Trial name
- NCT00098800
- Testing
- fenretinide
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Arizona
Adenocarcinoma of the Pancreas, Adenocarcinoma of the Stomach
Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
This phase I trial is studying the side effects and the best dose of veliparib when given together with capecitabine and oxaliplatin in treating patients with advanced solid tumors.
- Conditions
- Adenocarcinoma of the Pancreas, Adenocarcinoma of the Stomach, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier
- Trial name
- NCT01233505
- Testing
- veliparib, capecitabine, oxaliplatin
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)
brca1 Mutation Carrier, brca2 Mutation Carrier
Lysophosphatidic Acid Assay in Patients With Ovarian Cancer or Who Are at Risk for Ovarian Cancer
RATIONALE: Screening tests, such as the lysophosphatidic acid assay, may help doctors find cancer cells early and plan better treatment for ovarian cancer.
- Conditions
- brca1 Mutation Carrier, brca2 Mutation Carrier, Ovarian Cancer
- Trial name
- NCT00986206
- Testing
- Biomarker LPA and HE4
- Where
- United States
- Volunteers
- 525 people
- Sponsor
- Women and Infants Hospital of Rhode Island
BRCA1 Mutation Carrier, BRCA2 Mutation Carrier
Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This phase II trial studies how well veliparib works in treating patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer that has come back or does not respond to treatment.
- Conditions
- BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ovarian Epithelial Tumor, Recurrent Fallopian Tube Carcinoma
- Trial name
- NCT01540565
- Testing
- Laboratory Biomarker Analysis, Veliparib
- Where
- 153 sites in United States
- Volunteers
- 52 people
- Sponsor
- National Cancer Institute (NCI)
Cancer Genetics
Adaptation to Living With a BRCA1/2 Mutation
Background: Women who have a BRCA1/2 gene mutation have a very high risk of developing breast or ovarian cancer. They are also at increased risk of other developing other cancers.
- Trial name
- NCT01866865
- Where
- United States
- Volunteers
- 142 people, healthy volunteers welcome
- Sponsor
- National Human Genome Research Institute (NHGRI)